Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

European Industry Played Key Role In Mitigating COVID-19

Detailed Modelling And Industry Co-ordination Were Central To Managing Pandemic

Executive Summary

In the first part of an exclusive two-part interview, James Burt – Accord’s executive vice-president for Europe, the Middle East and North Africa – talks to Generics Bulletin about the key actions taken by the generics industry to mitigate the coronavirus pandemic, and the changed landscape that the off-patent arena can expect to see in future.

You may also be interested in...



Who’s Hired? Accord’s Burt Moves On

Accord has announced the appointment of a replacement for James Burt, who has stepped down from his role as executive vice-president for the Europe, Middle East and North Africa region. Meanwhile, other organizations including NeuClone, the Medicines Patent Pool, KVK Tech and Strides have also announced executive appointments.

EU Industry Welcomes New Schengen Strategy’s Green Lanes

Planned reforms to the EU’s Schengen open border system that will allow for transport “green lanes” to be reactivated when necessary have been welcomed by off-patent industry association Medicines for Europe.

Medicines For Europe Pushes Industrial Policy Goals

Ahead of an upcoming European Council meeting covering the EU’s industrial policy and ongoing response to the COVID-19 pandemic, Medicines for Europe has set out what it sees as key policy objectives to consider.

Related Content

Topics

UsernamePublicRestriction

Register

GB150120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel